How CDMO Partnerships Can Accelerate Cell and Gene Therapy Commercialization
Moving a cell or gene therapy from clinical development toward commercial supply requires coordination across process development, manufacturing, analytical testing, quality, regulatory readiness, and supply chain planning. Managing these activities internally can create significant operational and technical demands for biotechnology and pharmaceutical companies. Strategic end to end CDMO services can help developers bring these capabilities together under a coordinated manufacturing strategy. Instead of managing multiple specialized suppliers and internal functions independently, developers can work with a partner that supports several stages of the product lifecycle. For cell and gene therapy programs, this integrated model can improve continuity, simplify technology transfer, and help development teams prepare earlier for commercial manufacturing requirements. Why Commercialization Is Complex for Cell and Gene Therapies Cell and gene therapies have manufacturing requirements that d...